CCM
EVH icon

CAAS Capital Management’s Evolent Health EVH Stock Holding History

CAAS Capital Management’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-18,000
Closed -$505K – 774
2022
Q4 		$505K Buy
+18,000
New +$516K 0.03% 435

Other funds holding EVH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CAAS Capital Management's EVH Position: Q1 2023 in Review

CAAS Capital Management sold out of Evolent Health (EVH) in Q1 2023, closing a stake of 18,000 shares — an estimated $505K sold.

CAAS Capital Management first reported a position in EVH in Q4 2022 and held it in 1 quarter. The position peaked at $505K in Q4 2022. 240 funds tracked by Wall St. Rank hold EVH as of Q1 2023.

  • CAAS Capital Management reported no remaining Evolent Health position as of Q1 2023 after selling out during the quarter.
  • CAAS Capital Management sold 18,000 Evolent Health shares in Q1 2023, an estimated $505K.
  • CAAS Capital Management first reported a position in Evolent Health in Q4 2022 and held it in 1 quarter.
  • CAAS Capital Management's Evolent Health position peaked at $505K in Q4 2022.
  • 240 funds tracked by Wall St. Rank held Evolent Health as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.